Objectives: The pulsed dye laser (PDL) has long been the treatment of choice for port wine stains (PWS) and other vascular abnormalities. The goal of this round-table discussion is to consider a new generation of intense pulsed light (IPL) devices and understand how and why they rival traditional pulsed dye laser treatment of vascular and pigmentary abnormalities.

Introduction: Efforts have been made by PDL manufacturers to extend the the laser wavelength from 585 nm to 595-600 nm to improve depth of penetration to allow deeper vessels to be targeted with less purpura. Longer pulse durations and the advent of epidermal cooling have permitted the use of higher fluences and greater patient comfort.
The use of IPL was first suggested in 1998 and in subsequent years, despite encouraging clinical data and modification of irradiation parameters including pulse duration, fluence and wavelength, IPL technology has so far failed to win-over the die-hard PDL user.

Materials / method: Four companies with recent and innovative claims for their intense pulsed light (IPL) technology will participate in a round-table discussion. Three industry representatives and one dermatologist will respond to selected company slides presented by the session chairs to explore novel technology advances to explore the clinical and scientific evidence for these advances.

Results: IPL technology innovations for vascular treatments include: dual band filtering to reject low absorption wavebands, Rhodamine-doped xenon lamp source to focus energy in the PDL waveband, sub-millisecond pulse durations to mimic the PDL pulse duration and manipulation of the spatial and temporal IPL pulse profile.

Conclusion: Evidence-based clinical and scientific results confirm that modified IPL technology can match PDL clinical outcomes and deliver a better side-effect profile than traditional PWS.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。